11.80
-0.40 (-3.28%)
| Previous Close | 12.20 |
| Open | 12.01 |
| Volume | 783,904 |
| Avg. Volume (3M) | 1,053,522 |
| Market Cap | 1,189,982,848 |
| Price / Sales | 10.32 |
| Price / Book | 2.14 |
| 52 Weeks Range |
| Profit Margin | -82.68% |
| Operating Margin (TTM) | 31.61% |
| Diluted EPS (TTM) | -0.970 |
| Total Debt/Equity (MRQ) | 0.47% |
| Current Ratio (MRQ) | 14.62 |
| Operating Cash Flow (TTM) | -89.48 M |
| Levered Free Cash Flow (TTM) | -151.71 M |
| Return on Assets (TTM) | -25.43% |
| Return on Equity (TTM) | -17.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Day One Biopharmaceuticals, Inc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 16.98% |
| % Held by Institutions | 93.03% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Sep 2024 | 6,430,257 |
| Estuary Capital Management Lp | 30 Sep 2024 | 2,743,780 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 238.98%) | Buy |
| Median | 33.50 (183.90%) | |
| Low | 25.00 (B of A Securities, 111.86%) | Buy |
| Average | 33.00 (179.66%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 12.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 13 Jan 2025 | 33.00 (179.66%) | Buy | 11.80 |
| 31 Oct 2024 | 33.00 (179.66%) | Buy | 14.72 | |
| B of A Securities | 07 Jan 2025 | 25.00 (111.86%) | Buy | 12.40 |
| Jones Trading | 17 Dec 2024 | 34.00 (188.14%) | Buy | 12.64 |
| HC Wainwright & Co. | 31 Oct 2024 | 40.00 (238.98%) | Buy | 14.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2025 | Announcement | Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities |
| 17 Dec 2024 | Announcement | Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 20 Nov 2024 | Announcement | Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development |
| 18 Nov 2024 | Announcement | Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference |
| 30 Oct 2024 | Announcement | Day One Reports Third Quarter 2024 Financial Results and Corporate Progress |
| 16 Oct 2024 | Announcement | Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |